Global Polyclonal Antibodies Market Report 2024: Growth Analysis by TBRC
Posted by Ramakrishna TBRC on February 13th, 2024
The Polyclonal Antibodies Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Polyclonal Antibodies Market:
https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report
According to The Business Research Company’s Polyclonal Antibodies Global Market Report 2024, The polyclonal antibodies market size has grown strongly in recent years. It will grow from .35 billion in 2023 to .43 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to biomedical research demand, increased diagnostic applications, increase in chronic diseases, wide range of applications ..
The polyclonal antibodies market size is expected to see strong growth in the next few years. It will grow to .83 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expanding diagnostic technologies, therapeutic advancements, rise in infectious diseases, increased research funding, collaborations and partnerships.. Major trends in the forecast period include advancements in antibody engineering, growing role in cancer immunotherapy, rise of biosimilar polyclonal antibodies, application in neurological disorders, regulatory advances and compliance..
The increasing prevalence of cancer is expected to propel the growth of the polyclonal antibodies market going forward. Polyclonal antibodies are used in cancer research and treatment for biomarker detection, immunohistochemistry, targeted therapy, and immunotherapy, improving cancer diagnosis, treatment, and patient outcomes. The increase in cancer patients contributes to the growth of the polyclonal antibodies market. For instance, in September 2022, according to Cancer Australia, an Australia-based cancer control organization founded in Australia and its territories to help cancer sufferers and increase awareness of the disease, 2,572 new instances of stomach cancer are expected to be detected in 2022 (1,661 male cases and 911 female cases) in Australia. By the time they are 85 years old in 2022, a person has a 1 in 114 (or 0.87%) chance of having stomach cancer (1 in 1.1 or 87% for men and 1 in 167 or 0.60% for women). Therefore, the increasing prevalence of cancer drives the growth of the polyclonal antibodies market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10790&type=smp
The polyclonal antibodies market covered in this report is segmented –
1) By Product Type: Primary Antibody, Secondary Antibody
2) By Source: Rabbits, Goats, Sheep, Other Sources
3) By Application: Research, Diagnostics, Therapy
4) By End-User: Academic and Research Center , Pharmaceutical and Biotechnology Companies, Diagnostic Centers , Hospitals
Research and development are the key trend gaining popularity in the polyclonal antibodies market. Major companies involved in polyclonal antibodies are focused on research and development to improve their observation power and sustain their position in the market. For instance, In July 2022, GigaGen Inc., a US-based biotechnology company, published a research article titled ‘GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,’ in the international, peer-reviewed journal Pathogens. This paper describes the company's recombinant polyclonal product that targets SARS-CoV-2, GIGA-2050, for the first time, as well as the GMP (good manufacturing practice) production and IND (Investigational novel Drug)-enabling investigations of its novel class of pharmaceuticals, recombinant polyclonal antibodies. GIGA-2050 has over 12,000 antibodies from a single master cell bank (MCB). Before GIGA-2050, manufacturing procedures for considerably smaller recombinant antibody mixes frequently involved creating separate MCBs for each monoclonal antibody and combining the MCBs before manufacture.
The polyclonal antibodies market report table of contents includes:
1. Executive Summary
2. Polyclonal Antibodies Market Characteristics
3. Polyclonal Antibodies Market Trends And Strategies
4. Polyclonal Antibodies Market - Macro Economic Scenario
5. Global Polyclonal Antibodies Market Size and Growth
....
31. Global Polyclonal Antibodies Market Competitive Benchmarking
32. Global Polyclonal Antibodies Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Polyclonal Antibodies Market
34. Polyclonal Antibodies Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
